MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, PHGE had -$13,093K decrease in cash & cash equivalents over the period. -$26,392K in free cash flow.

Cash Flow Overview

Change in Cash
-$13,093K
Free Cash flow
-$26,392K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Ipr&d impairment
    • Issuance of common stock under i...
    • Issuance of common warrants unde...
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Income from change in fair value...
    • Other account payables
    • Others

Cash Flow
2025-12-31
Stock-based compensation
2,091
Gain from early lease termination
2,949
Finance expense (income), net
-256
Revaluation of contingent consideration
-77
Income from change in fair value of warrants
6,111
Loss from sale and disposal of fixed assets, net
-205
Ipr&d impairment
11,842
Other long-lived asset impairment
1,653
Other current assets
-2,243
Trade account payables
1,238
Other account payables
-3,430
Net change in operating leases
-74
Depreciation
2,922
Net loss
-36,199
Private placement warrants issuance cost
0
Changes in contract liability
0
Goodwill impairment
0
Net cash used in operating activities
-26,390
Purchase of property and equipment
2
Proceeds from sale of property and equipment
110
Cash and restricted cash acquired from the apt acquisition
0
Net cash provided by investing activities
108
Issuance of common stock under february 2025 spa
996
February 2025 spa issuance costs
118
Issuance of common warrants under february 2025 spa
4,531
Issuance of common stock under inducement letter agreements
6,473
Pre-funded warrants exercise
2
Issuance of common stock under open market sales agreement, net of issuance costs
1,305
Repayment of long-term debt
0
Issuance of private placement warrants under march 2024 pipe
0
Issuance of redeemable convertible preferred shares under march 2024 pipe
0
March 2024 pipe issuance costs
0
Net cash provided by financing activities
13,189
Increase (decrease) in cash and cash equivalents and restricted cash
-13,093
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Issuance of common stockunder inducement...$6,473K Issuance of commonwarrants under february...$4,531K Issuance of common stockunder open market...$1,305K Issuance of common stockunder february 2025...$996K Proceeds from sale ofproperty and equipment$110K Pre-funded warrantsexercise$2K Net cash provided byfinancing activities$13,189K Net cash provided byinvesting activities$108K Canceled cashflow$118K Canceled cashflow$2K Increase (decrease) incash and cash...-$13,093K Canceled cashflow$13,297K Ipr&d impairment$11,842K Depreciation$2,922K Other current assets-$2,243K Stock-based compensation$2,091K Other long-livedasset impairment$1,653K Trade accountpayables$1,238K Finance expense(income), net-$256K Loss from sale anddisposal of fixed assets,...-$205K February 2025 spaissuance costs$118K Purchase of property andequipment$2K Net cash used inoperating activities-$26,390K Canceled cashflow$22,450K Net loss-$36,199K Income from change infair value of...$6,111K Other accountpayables-$3,430K Gain from early leasetermination$2,949K Revaluation of contingentconsideration-$77K Net change inoperating leases-$74K

BiomX Inc. (PHGE)

BiomX Inc. (PHGE)